Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (311-320 of 365) with videos related to

Pageof 37
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemiaAaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Nature Communications|February 16, 2025
Melanocortin 3 receptor regulates hepatic autophagy and systemic adiposityTushar P Patel, Joo Yun Jun, Arnold Y Seo, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
Plos One|March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic reviewYaping Chang, Gordon H Guyatt, Trevor Teich, et al.
American Journal of Hematology|October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult diseaseMark R Litzow, Xin V Wang, Martin P Carroll, et al.
Blood Cancer Journal|October 6, 2025
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosisAndrew Palmer, Garth Rauscher, Alexa Schoen, et al.
Cell Reports|April 21, 2015
Central role of ULK1 in type I interferon signalingDiana Saleiro, Swarna Mehrotra, Barbara Kroczynska, et al.
Haematologica|January 15, 2026
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemiaIvy E Abraham, Garth H Rauscher, Jerry Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Pageof 37

Showing results (311-320 of 365) with videos related to

Sort By:
Pageof 37
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2009
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemiaAaron D Schimmer, Elihu H Estey, Gautam Borthakur, et al.
American Journal of Hematology|February 12, 2024
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centersYasmin Abaza, Eric S Winer, Guru Subramanian Guru Murthy, et al.
Nature Communications|February 16, 2025
Melanocortin 3 receptor regulates hepatic autophagy and systemic adiposityTushar P Patel, Joo Yun Jun, Arnold Y Seo, et al.
Cancer|October 6, 2023
Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemiaFabio Efficace, Francesco Cottone, Betina Yanez, et al.
Plos One|March 30, 2021
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic reviewYaping Chang, Gordon H Guyatt, Trevor Teich, et al.
American Journal of Hematology|October 30, 2018
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult diseaseMark R Litzow, Xin V Wang, Martin P Carroll, et al.
Blood Cancer Journal|October 6, 2025
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosisAndrew Palmer, Garth Rauscher, Alexa Schoen, et al.
Cell Reports|April 21, 2015
Central role of ULK1 in type I interferon signalingDiana Saleiro, Swarna Mehrotra, Barbara Kroczynska, et al.
Haematologica|January 15, 2026
Clinical and sociodemographic predictors of intensive care unit admission following chemotherapy in acute myeloid leukemiaIvy E Abraham, Garth H Rauscher, Jerry Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2023
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AMLKeith W Pratz, Mohamad Cherry, Jessica K Altman, et al.
Pageof 37